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Successful re-introduction of lamotrigine after initial
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The aim of this study was to determine whether lamotrigine can be re-introduced safely and with a benefit in young people who
previously had a mild rash associated with the first introduction of this drug. In the first 150 young people (5–19 years old)
treated with lamotrigine in a special centre for epilepsy, seven developed a mild rash soon after starting the drug. In none of
these cases was the rash severe, nor was there any mucous membrane involvement. The lamotrigine was stopped immediately
when the rash was identified and was subsequently re-introduced, using a special very-low-dose-escalation regime, starting
with 0.1 mg/day total daily dose, after periods ranging from 47 to 236 days. It was possible to re-introduce the lamotrigine
without recurrence of persistent rash and without any adverse effects in all seven cases. The re-introduction of lamotrigine
was associated with improvement in five of the seven cases. It is recommended that lamotrigine is stopped as soon as any rash
attributable to the drug develops but it may be possible to re-introduce the drug after mild rash using a very-slow-dose-escalation
regime, with a benefit in at least some cases.
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INTRODUCTION
Skin rash is one of the commonest adverse effects of
lamotrigine. Messenheimer1 has recently carried out a
comprehensive review of this subject. The incidence
appears to relate closely to dose escalation; for exam-
ple, within a single study, the rash rate varied from 5%
to 39%, depending on dose escalation2. Rash is more
likely to occur if the patient is already taking sodium
valproate, which prolongs the half-life of lamotrigine3.
Serious reactions such as Stevens–Johnson syndrome
and toxic epidermal necrolysis have been reported and
fatalities have occurred4, 5.
PATIENTS AND METHODS
In the first 150 children and teenagers (age range 5–
19 years) treated at a special epilepsy centre, seven
developed a mild rash. There was no history of rash
with previous antiepileptic medication. Mild in this
context was defined as including none of the follow-
ing: mucous membrane involvement, blisters/bullae
or extensive desquamation. The term mild also im-
plied that there was no fever, lymphadenopathy or sys-
temic involvement attributable to the drug. In every
case the lamotrigine was discontinued immediately
but was re-introduced, using a special very-slow-dose-
escalation regime, commencing with 0.1 mg/day total
daily dose (see Table 1). Eames6 had suggested that
such a regime might be used to prevent rash devel-
oping with carbamazepine. The lamotrigine was re-
introduced because seizure control was unsatisfactory
with other available drugs. In some cases there had
been an apparent good initial response to lamotrigine
but in other cases the drug had not been given for long
enough to allow any assessment to be made. The lam-
otrigine was re-introduced after a minimum period of
6 weeks (47–236 days) from the time when the drug
was initially stopped. The minimum of 6 weeks was
chosen to allow plenty of time for any initial reaction
to subside completely.
The low doses were achieved by breaking the scored
5 mg dispersible tablet into quarters and dispersing a
quarter tablet into 12.5 ml of water. 1 ml of this liquid
was equivalent to 0.1 mg of lamotrigine. Before the
dispersible tablets became available, the smaller doses
were obtained by grinding a 25 mg tablet; the powder
obtained was carefully homogenized into lactose pow-
der which was weighed to give the appropriate doses.
The powder was placed into standard gelatine capsules
giving the appropriate dose at each stage.
1059–1311/00/040282 + 05 $35.00/0 c© 2000 BEA Trading Ltd
Successful re-introduction of lamotrigine after initial rash 283
Table 1: Very-low-dose-escalation re-introduction regime for
lamotrigine.
Week 1 0.1 mg dailya
Week 2 0.1 mg bd
Week 3 0.2 mg bd
Week 4 and 5 1 mg daily
Week 6 and 7 2 mg daily
Week 8 4 mg daily
Week 9 and 10 6.25 mg daily
Week 11 and 12 12.5 mg daily
After week 12 the dose was doubled at intervals of no less than 2
weeks until a dose of 50 mg was reached. No subsequent dose in
increments exceeded 50 mg and the increases were carried out no
more frequently than at fortnightly intervals.
a Note: 0.1 mg is the total daily dose: not to be confused with the
0.1 mg/kg daily used as a standard introduction for patients taking
valproate at Lingfield—see text.
RESULTS
These are shown in Table 2.
DISCUSSION
The development of rash with lamotrigine has been
linked to the initial dose and the rate of dose-
escalation. This was clearly shown in the study of
lamotrigine in the prophylaxis of migraine2. In that
study, a fixed dose regime of 200 mg a day resulted in
the withdrawal of lamotrigine because of rash in 7 of
18 patients (39%) whereas the group in which the lam-
otrigine was escalated more slowly, beginning with
25 mg per day and increasing at two-week intervals
to 50 mg daily and then 200 mg daily resulted in a
withdrawal rate of 1 in 19 (5%), which was similar
to placebo. A number of the cases reported here were
prescribed lamotrigine before the current UK dosing
regimes (see Table 3a and b), were recommended.
The dose regimes used for cases 1, 2, 3 and 7 were
not within these recommendations but the dosages for
cases 4, 5 and 6 were. This raises the question of
whether these recommendations are appropriate. The
regime adopted at St Piers Lingfield over recent years
is more conservative and simpler. The dose is com-
menced at 1 mg/kg/day for those not taking sodium
valproate and 0.1 mg/kg/day for those who are tak-
ing sodium valproate. The dose is doubled at two-
weekly intervals but in no case does any dose incre-
ment exceed 50 mg. Since this regime was introduced,
only one mild rash has been seen in over 100 cases. It
should be noted that the current UK guidelines are due
for revision and that the US guidelines have recently
been revised. The current US guidelines are close to
the practice adopted at Lingfield in recent years (see
Table 3c and d).
Were all the rashes in this series clearly related to the
lamotrigine? The timing of the rash is strongly pre-
sumptive evidence in most cases, although there was
possibly some doubt about case 2, because he had de-
veloped a rash at other times, and in case 5 because
he had signs of an upper respiratory tract infection and
was treated with amoxycillin which is known to be as-
sociated with a similar type of rash. The evidence for
the rash being related to the lamotrigine is stronger in
case 4 because a mild rash recurred when the lamot-
rigine was recommenced.
The very-slow-introduction regime was based on
previous work with carbamazepine. Eames6 reported
on seven cases of rash with carbamazepine managed
by ‘desensitization’. The dose-escalation regime he
used was based on a single case-report by Smith and
Newton7. Chadwick et al.8 had also linked the speed
of dose escalation with incidence of rash associated
with carbamazepine. The regime used in our study
closely follows that of Eames for carbamazepine.
Whether this regime represents a true ‘desensitization’
or not remains open to debate. Those using this regime
for carbamazepine have adopted a policy of continuing
the drug if a very mild rash occurs during the ‘desen-
sitization’ period. The dose may be held at the same
level if a mild rash occurs and if, in the opinion of
the clinician, there are no other untoward signs such
as systemic illness, suggesting that the drug should
be stopped. The approach taken is that a mild rash at
such a low dose is unlikely to develop into a serious
rash. Although limited experience using this regime
has not led to any serious rashes, it cannot be con-
cluded that serious rashes could never occur in such
circumstances. Re-introduction should only be under-
taken if close medical supervision can be offered so
that if a patient were to develop any symptoms caus-
ing concern, immediate action could be taken.
Is it necessary to use such a slow re-introduction
regime? Schlumberger et al.3 described the successful
re-introduction of lamotrigine in four out of five pa-
tients after sodium valproate was stopped. However,
the re-introduction regime was not stated. Tavernor
et al.9 described seven patients, four of whom were
children or teenagers, in whom lamotrigine was re-
introduced after initial rash. A further patient, an 8-
year-old child, developed a rash after taking lamotrig-
ine for 7 months but the lamotrigine was not stopped
completely before being increased again, implying
that this was not, strictly speaking, re-introduction of
the drug. In two of these cases the dose was built over a
period of at least 6 months, representing a slower over-
all dose escalation rate but the lamotrigine was recom-
menced at much higher starting doses: 12.5 mg daily
or on alternate days. In one of these cases the rash re-
curred when the drug was recommenced at 12.5 mg
on alternate days but it was possible to re-introduce
lamotrigine again, using an even slower escalation
regime: 0.5 mg on alternate days, slowly building up
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Table 2: Summary of seven cases of rash associated with lamotrigine.
No. A S Vpa Other Start Dose Start Dose Dose > Dose > Rash Fever Lymph- Other Re- Outcome
g e comed comed dose weeks dose weeks 3–4 recom recom on day adeno- cause started
e x mg/day 3–4 (mg/kg/ mg/kg/ (UK) (US) number pathy likely after
mg/day day) day (days)
1 14 M No Cbz 100 150 1.8 4.4 Yes Yes 24 No No No 236 Seizure-free
2 6 M No Pb 50 100a 2 4.2a Yes Yes 13 No No Possibleb 47 Seizure-free
3 15 M Yes Cbz 12.5 25 0.3 0.6 Yes Yes 57 No No No 76 Nonconvul-
sive status
epilepticus
episodes
abated
4 14 M No Cbz 25 50 0.6 1.2 No No 26 Yesc No Noc 52 Seizure not
controlled.
Lamotrigine
discontinued
5 18 M No Esm, 50 (stopped 1.1 — No Yes 13 Nod Yesd Possible 92 Seizures
Vgb, on day 13) amoxy- improved
Cbz cillind but
continued
6 16 M Yes Cbz 5 (stopped 0.1 — No No 3 No No No 47 No benefit
on day 3)
7 11 M Yes — 12.5 25 0.4 0.7 Yes Yes 21 No No No 161 Absence
seizures
fully
controlled
a Increase actually on day 13. Rash appeared that day and lamotrigine then stopped.
b Had previously had occasional rashes with no apparent cause.
c Associated with inflamed pharynx, mildly inflamed tympanic membrane and green nasal discharge.
Because he also developed a very mild rash 22 days after re-introduction, the initial rash was considered to be attributable to the lamotrigine.
Because the dose at that stage of the re-introduction was still very low (0.4 mg daily total dose) and the rash very mild, the drug was continued
and the rash resolved.
d Ten days previously he had been febrile with lymphadenopathy and an inflamed right tympanic membrane. Amoxycillin was prescribed.
Comed = comedication,
Vpa = sodium valproate, Cbz = carbamazepine, Pb= phenobarbital, Esm = ethosuximide, Vgb = vigabatrin
Dose > recom = dose exceeds recommended schedule.
Table 3a: Current UK lamotrigine dose-escalation schedule for children aged 2–12 years on combined drug therapy.
Concurrent Weeks 1–2 Weeks 3–4 Maintenance
AED dose
VPA 0.2 mg/kg/day 0.5 mg/kg/day 1–5 mg/kg/day
(once daily) (once daily) (once daily or in two divided doses) increasing every 1–2 weeks by
1 mg/kg/day increments
EIAEDsa 2 mg/kg/day 5 mg/kg/day 5–15 mg/kg/day
(in two divided doses) (in two divided doses) (in two divided doses) increasing by 2–3 mg/kg every 1–2 weeks)
a EIAED = enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital and carbamazepine. Patients who are taking both valproate
(VPA) and an EIAED should be dosed according to the co-administration with VPA guidelines.
to 12.5 mg over 6 months, with no recurrence of the
rash. It could be argued that 6 months is unnecessar-
ily long. The most important period appears to be the
first 6–8 weeks of treatment, since most rashes occur
over this time. Whether the very-low-dose-escalation
regime used over the first 6–8 weeks followed by a
more rapid escalation would be equally tolerated re-
mains unclear.
Would the incidence of the serious reactions re-
ported in a number of papers4, 5, 10, 11 be reduced by a
slower dose escalation? In a recent publication, factors
associated with serious rash in children taking lamot-
rigine were examined, using available data from clini-
cal trials12. A higher initial dose or more rapid dose
escalation than currently recommended were identi-
fied as associated factors in 8 of the 10 cases. The
weight of evidence suggests that starting dose and
dose-escalation rates should be kept well within the
pharmaceutical company guidelines13. It will be of
great interest to discover whether the more conserva-
tive regime already recommended in the US will lead
to a lower rate of both serious and mild rashes.
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Table 3b: Current UK lamotrigine dose-escalation schedule for adults and children over 12 years on combined drug therapy.
Concurrent Weeks 1–2 Weeks 3–4 Maintenance
AED dose
VPA 12.5 mg 25 mg once daily 100–200 mg
(given as 25 mg onalternative days) (once daily or in two divided doses) increasing by
25–50 mg every 1–2 weeks)
EIAEDsa 50 mg 100 mg 200–400 mg
(daily) (in two divided doses) (in two divided doses increasing by 100 mg every
1–2 weeks)
a EIAED = enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital and carbamazepine. Patients who are taking both valproate
(VPA) and an EIAED should be dosed according to the co-administration with VPA guidelines.
Table 3c: Current US lamotrigine dose-escalation schedule for children 2–12 years. (Based on package insert 1998).
Concurrent Weeks 1–2 Weeks 3–4 Maintenance
AED dose
VPA 0.15 mg/kg/day 0.3 mg/kg/day 1–5 mg/kg/day
once daily or in two divided doses once daily or in two divided doses increasing every 1–2 weeks by
up to 0.3 mg/kg/day increments
EIAEDsa 0.6 mg/kg/day 1.2 mg/kg/day 5–15 mg/kg/day
once daily or in two divided doses once daily or in two divided doses increasing every 1–2 weeks by
up to 1.2 mg/kg/day increments
a EIAED = enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital and carbamazepine. Patients who are taking both valproate
(VPA) and an EIAED should be dosed according to the co-administration with VPA guidelines.
Table 3d: Current US lamotrigine dose-escalation schedule for adults and children over 12 years.
Concurrent Weeks 1–2 Weeks 3–4 Maintenance
AED dose
VPA 25 mg every other day 25 mg daily 100–400 mg daily or in two divided doses
increasing by 25–50 mg/day every 1–2 weeks.
Usual maintenance dose in patients adding lamotrigine
to VPA alone ranges from 100–200 mg/day.
EIAEDsa 50 mg daily 100 mg daily in two divided doses 300–500 mg daily in two divided doses
increasing by 100 mg/day every 1–2 weeks
a EIAED = enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital and carbamazepine. Patients who are taking both valproate
(VPA) and an EIAED should be dosed according to the co-administration with VPA guidelines.
CONCLUSIONS AND RECOMMENDATIONS
Lamotrigine was successfully re-introduced in seven
children and teenagers who developed rash when the
drug was initially prescribed. Five of these seven
young people appeared to benefit from the drug. When
using any drug, the risk/benefit ratio must be consid-
ered. Although avoiding the initial rash by using low
starting doses and escalation rates would be the pre-
ferred approach, it seems reasonable to consider re-
introduction of lamotrigine after initial rash using a
very-low-dose-escalation regime in children with se-
vere or disabling epilepsy that has not responded ad-
equately to other drugs. Until more data is available,
it is strongly recommended that lamotrigine should be
stopped immediately if a rash attributable to the drug
occurs and that re-introduction after initial rash should
only be undertaken in centres capable of providing
close supervision. Lamotrigine should probably not be
re-introduced if the initial adverse effect was serious.
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